Search research articles
Contact Us
Filters
Showing results (11-20 of 32) with videos related to
Page
of 4
Sort By:
BMC Public Health
|
April 22, 2018
Development and validation of PozQoL: a scale to assess quality of life of PLHIV
Graham Brown, Gosia Mikołajczak, Anthony Lyons, et al.
BMC Neurology
|
March 20, 2021
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
David Kudrow, Roger K Cady, Brent Allan, et al.
AIDS Research and Therapy
|
November 10, 2020
Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies
Jillian S Y Lau, Miranda Z Smith, Brent Allan, et al.
Neuropsychiatric Disease and Treatment
|
December 12, 2019
Validity and Reliability Study of the Chinese (Traditional) Version of the Devereux Early Childhood Assessment for Toddlers (DECA-T)
Sophie Hsin-Yi Liang, Jen-Yu Chou, Yu-Yu Wu, et al.
Clinical Therapeutics
|
November 30, 2020
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
Timothy R Smith, Marina Janelidze, George Chakhava, et al.
AIDS Research and Human Retroviruses
|
October 15, 2019
Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies
Jillian S Y Lau, Miranda Z Smith, Brent Allan, et al.
Cephalalgia : an International Journal of Headache
|
February 21, 2020
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina, Joel Saper, Roger Cady, et al.
The Journal of Headache and Pain
|
October 7, 2020
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
Stephen Silberstein, Merle Diamond, Nada A Hindiyeh, et al.
HIV Medicine
|
August 15, 2025
Strategies to achieve the UNAIDS 95% HIV diagnosis target in Australia: Insights from a multidisciplinary roundtable
Brent Clifton, Phillip Keen, Janine Trevillyan, et al.
Neurology
|
March 27, 2020
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B Lipton, Peter J Goadsby, Jeff Smith, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 32) with videos related to
Sort By:
Page
of 4
BMC Public Health
|
April 22, 2018
Development and validation of PozQoL: a scale to assess quality of life of PLHIV
Graham Brown, Gosia Mikołajczak, Anthony Lyons, et al.
BMC Neurology
|
March 20, 2021
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
David Kudrow, Roger K Cady, Brent Allan, et al.
AIDS Research and Therapy
|
November 10, 2020
Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies
Jillian S Y Lau, Miranda Z Smith, Brent Allan, et al.
Neuropsychiatric Disease and Treatment
|
December 12, 2019
Validity and Reliability Study of the Chinese (Traditional) Version of the Devereux Early Childhood Assessment for Toddlers (DECA-T)
Sophie Hsin-Yi Liang, Jen-Yu Chou, Yu-Yu Wu, et al.
Clinical Therapeutics
|
November 30, 2020
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
Timothy R Smith, Marina Janelidze, George Chakhava, et al.
AIDS Research and Human Retroviruses
|
October 15, 2019
Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies
Jillian S Y Lau, Miranda Z Smith, Brent Allan, et al.
Cephalalgia : an International Journal of Headache
|
February 21, 2020
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina, Joel Saper, Roger Cady, et al.
The Journal of Headache and Pain
|
October 7, 2020
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
Stephen Silberstein, Merle Diamond, Nada A Hindiyeh, et al.
HIV Medicine
|
August 15, 2025
Strategies to achieve the UNAIDS 95% HIV diagnosis target in Australia: Insights from a multidisciplinary roundtable
Brent Clifton, Phillip Keen, Janine Trevillyan, et al.
Neurology
|
March 27, 2020
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B Lipton, Peter J Goadsby, Jeff Smith, et al.
Page
of 4